UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-6 (pp-GalNAc-T6): Role in cancer and prospects as a drug target

Samantha Banford, David Timson

Research output: Contribution to journalArticle

Abstract

UDP-N-acetyl-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 (pp-GalNAc-T6) is a member of the N-acetyl-d-galactosamine transferase family. It catalyzes the addition of N-acetyl-d-galactosamine to proteins, often the first step in O-glycosylation of proteins. Glycosylated proteins play important roles in vivo in the cell membrane. These are often involved in cell-cell adhesion, cytoskeleton regulation and immune recognition. pp-GalNAc-T6 has been shown to be upregulated in a number of types of cancer. Abnormally glycosylated forms of mucin 1 (substrate of the enzyme), are used clinically as a biomarker for breast cancer. There is potential for other products of the pp-GalNAc-T6 catalyzed reaction to be used. It is also possible that pp-GalNAc-T6 itself could be used as a biomarker, since levels of this protein tend to be low in non-malignant tissues. pp-GalNAc-T6 has been implicated in malignant transformation and metastasis of cancer cells. As such, it has considerable potential as a target for chemotherapy. To date, no selective inhibitors of the enzyme have been identified. However, general inhibitors of the enzyme family result in reduced cell surface O-linked glycosylation and induce apoptosis in cultured cells. Thus, a selective inhibitor of pp-GalNAc-T6 is likely to target cancer cells and could be developed into a novel anticancer therapy.
Original languageEnglish
Pages (from-to)53-61
Number of pages9
JournalCurrent Cancer Drug Targets
Volume17
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Acetylgalactosamine
Uridine Diphosphate
Galactosamine
Pharmaceutical Preparations
Neoplasms
Enzyme Inhibitors
Transferases
Glycosylation
Biomarkers
Mucin-1
Proteins
Cytoskeleton
Cell Adhesion
polypeptide N-acetylgalactosaminyltransferase
UDP-N-acetylgalactosamine polypeptide N-acetylgalactosaminyltransferase 6
Cultured Cells
Cell Membrane
Apoptosis
Breast Neoplasms
Neoplasm Metastasis

Bibliographical note

The published manuscript is available via https://benthamscience.com/journals/current-cancer-drug-targets/volume/17/issue/1/page/53/

Keywords

  • UDP-GalNAc
  • UDP-N-acetyl-D-galactosamine
  • polypeptide N-acetylgalactosaminyltransferase-6
  • cancer
  • metastasis
  • biomarker
  • GALNT6

Cite this

@article{8573e8e2012c4672b19a8fc6526472d0,
title = "UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-6 (pp-GalNAc-T6): Role in cancer and prospects as a drug target",
abstract = "UDP-N-acetyl-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 (pp-GalNAc-T6) is a member of the N-acetyl-d-galactosamine transferase family. It catalyzes the addition of N-acetyl-d-galactosamine to proteins, often the first step in O-glycosylation of proteins. Glycosylated proteins play important roles in vivo in the cell membrane. These are often involved in cell-cell adhesion, cytoskeleton regulation and immune recognition. pp-GalNAc-T6 has been shown to be upregulated in a number of types of cancer. Abnormally glycosylated forms of mucin 1 (substrate of the enzyme), are used clinically as a biomarker for breast cancer. There is potential for other products of the pp-GalNAc-T6 catalyzed reaction to be used. It is also possible that pp-GalNAc-T6 itself could be used as a biomarker, since levels of this protein tend to be low in non-malignant tissues. pp-GalNAc-T6 has been implicated in malignant transformation and metastasis of cancer cells. As such, it has considerable potential as a target for chemotherapy. To date, no selective inhibitors of the enzyme have been identified. However, general inhibitors of the enzyme family result in reduced cell surface O-linked glycosylation and induce apoptosis in cultured cells. Thus, a selective inhibitor of pp-GalNAc-T6 is likely to target cancer cells and could be developed into a novel anticancer therapy.",
keywords = "UDP-GalNAc, UDP-N-acetyl-D-galactosamine, polypeptide N-acetylgalactosaminyltransferase-6, cancer, metastasis, biomarker, GALNT6",
author = "Samantha Banford and David Timson",
note = "The published manuscript is available via https://benthamscience.com/journals/current-cancer-drug-targets/volume/17/issue/1/page/53/",
year = "2017",
month = "1",
day = "1",
doi = "10.2174/1568009616666160922102641",
language = "English",
volume = "17",
pages = "53--61",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
number = "1",

}

TY - JOUR

T1 - UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-6 (pp-GalNAc-T6): Role in cancer and prospects as a drug target

AU - Banford, Samantha

AU - Timson, David

N1 - The published manuscript is available via https://benthamscience.com/journals/current-cancer-drug-targets/volume/17/issue/1/page/53/

PY - 2017/1/1

Y1 - 2017/1/1

N2 - UDP-N-acetyl-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 (pp-GalNAc-T6) is a member of the N-acetyl-d-galactosamine transferase family. It catalyzes the addition of N-acetyl-d-galactosamine to proteins, often the first step in O-glycosylation of proteins. Glycosylated proteins play important roles in vivo in the cell membrane. These are often involved in cell-cell adhesion, cytoskeleton regulation and immune recognition. pp-GalNAc-T6 has been shown to be upregulated in a number of types of cancer. Abnormally glycosylated forms of mucin 1 (substrate of the enzyme), are used clinically as a biomarker for breast cancer. There is potential for other products of the pp-GalNAc-T6 catalyzed reaction to be used. It is also possible that pp-GalNAc-T6 itself could be used as a biomarker, since levels of this protein tend to be low in non-malignant tissues. pp-GalNAc-T6 has been implicated in malignant transformation and metastasis of cancer cells. As such, it has considerable potential as a target for chemotherapy. To date, no selective inhibitors of the enzyme have been identified. However, general inhibitors of the enzyme family result in reduced cell surface O-linked glycosylation and induce apoptosis in cultured cells. Thus, a selective inhibitor of pp-GalNAc-T6 is likely to target cancer cells and could be developed into a novel anticancer therapy.

AB - UDP-N-acetyl-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 (pp-GalNAc-T6) is a member of the N-acetyl-d-galactosamine transferase family. It catalyzes the addition of N-acetyl-d-galactosamine to proteins, often the first step in O-glycosylation of proteins. Glycosylated proteins play important roles in vivo in the cell membrane. These are often involved in cell-cell adhesion, cytoskeleton regulation and immune recognition. pp-GalNAc-T6 has been shown to be upregulated in a number of types of cancer. Abnormally glycosylated forms of mucin 1 (substrate of the enzyme), are used clinically as a biomarker for breast cancer. There is potential for other products of the pp-GalNAc-T6 catalyzed reaction to be used. It is also possible that pp-GalNAc-T6 itself could be used as a biomarker, since levels of this protein tend to be low in non-malignant tissues. pp-GalNAc-T6 has been implicated in malignant transformation and metastasis of cancer cells. As such, it has considerable potential as a target for chemotherapy. To date, no selective inhibitors of the enzyme have been identified. However, general inhibitors of the enzyme family result in reduced cell surface O-linked glycosylation and induce apoptosis in cultured cells. Thus, a selective inhibitor of pp-GalNAc-T6 is likely to target cancer cells and could be developed into a novel anticancer therapy.

KW - UDP-GalNAc

KW - UDP-N-acetyl-D-galactosamine

KW - polypeptide N-acetylgalactosaminyltransferase-6

KW - cancer

KW - metastasis

KW - biomarker

KW - GALNT6

U2 - 10.2174/1568009616666160922102641

DO - 10.2174/1568009616666160922102641

M3 - Article

VL - 17

SP - 53

EP - 61

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 1

ER -